3rd ESTRO Forum 2015 prescription dose was escalated to the maximum level achievable for each patient according to predefined organs at risk (OAR) toxicity and dose constraints. Radiobiological models were used to predict a patient-specific radiotherapy (RT) dose associated with a 10% risk of grade 3 and above pneumonitis which was then constrained to a prescription dose of 63-73 Gy in 30# for IDEAL-CRT (plus concurrent chemotherapy) and 55-65 Gy in 20# for I-START. These are the first multi-centre trials in the UK to investigate isotoxic dose escalation and as such incorporated a thorough Quality Assurance (QA) programme to ensure protocol compliance. Materials and Methods: RT plans were produced across 8 centres for IDEAL and 12 centres for I-START. Full 3D RT planning data was submitted to a central QA contact. All RT plans and plan assessment forms were analysed for quality and protocol compliance. Results: Between 2010 and 2014, 84 and 81 patients were recruited to IDEAL-CRT and I-START respectively. Table 1 shows the average doses received by OAR and targets compared to the doses stated in the protocol.
Purpose/Objective: Concurrent chemo-radiation (CRT) is the treatment of choice for local advanced NSCLC patients. Despite the curative intent of the treatment, survival is poor with a median survival of about 16-18 months (m) and a 5 year (y) survival of 15%. The loco-regional control rate at 2 y is only about 30% in clinical trials. This randomized phase-II trial tested a dose intense oral vinorelbine (Nav) regimen with two doses of RT, 60 Gy/30 F (arm A) and 66 Gy/33 F (arm B). Materials and Methods: Before randomization to arm A or B, the patients were treated with 2 cycles of induction chemotherapy (Carboplatin+Nav). In both arms, Nav was given as concurrent chemotherapy (a fixed dose of 50 mg 3/week for the full course of CRT). Follow-up CT-scans were performed every 3 m starting 1 m after commencing radiotherapy for 2 y and then every 6 m. As part of the protocol, a PET-CT scan was conducted 9 m after randomization. The primary endpoint was the Local Progression Free Survival Rate (LPFSR). The goal of the study was within the 95% confidence interval (95%CI) to have a LPFSR at 9 m of 80%. Log rank tests were used to test survival. Results: In arm A and B, 59 and 58 patients were eligible. The two arms were well balanced. The minimum and median potential follow-up was 14.5 and 32.6 m, respectively. The median number of Nav was 18 x in arm A and 20 x in arm B. Of the patients, 10% had ≤12 x Nav. The LPFSR at 9 m was in arm A: 54% (95%CI: 43%; 64%), and in arm B: 60% (95% CI: 49%; 71%), and the LPFSR at 1 and 2 year was 40% and 32% in arm A, and 49% and 44%, in arm B. The median LPFSR was 10.0 m and 10.9 m in arm A and B (p=0.57). The median OS was 23.3 m in arm A, and 25.3 m in arm B. The 1 and 2 y overall survival was 83% and 46% in arm A, and 81% and 51% in arm B (p=0.67). This was similar to the survival in a comparable reference group. Side effects: Hematological Grade (G) 4 side effects were observed in 2 patients in each arm. Dysphagia and dyspnoe tended to be higher in arm B. One G4 pneumonitis was observed in arm A and 1 G5 in arm B. Mean weight loss was 2.8% in arm A, and of 1.5% in arm B. The difference was not statistically significant. Weight loss of 10-20% was observed in 7% and 3% of the patients in arm A and B, respectively; but no one had a G3 weight loss (≥20%). A late effect esophageal stricture/ulceration G3 or more occurred in 3 (5%) of the patients in arm A and 4 (7%) in arm B, and one of these in arm B was a G5 fistula at the site of the primary tumor. Conclusions: The phase II goal was not met in neither of the treatment arms. This may be caused by the extensive use of PET-CT scan in the study revealing progressions earlier than was expected from previous studies, or it could have been caused by the omission of concurrent cisplatin. The survival of the two arms was however comparable. Since both treatment arms were well tolerated with no differences in toxicity between the arms, and the 66 Gy arm had a trend to better loco-regional control, we have chosen this treatment arm (with cisplatin added) as the reference arm in a phase III 3rd ESTRO Forum 2015 S123 trial.
Symposium: Elderly: Health economics

SP-0243 Cost-effectiveness data to guide treatment decisions for elderly patients: focus on radiotherapy A. Louie 1 1 London Health Sciences Centre, Department of Radiation Oncology, London, Canada
As a disease of the elderly, cancer poses a unique public health problem worldwide. Elderly patients with cancer are less likely to receive guideline-based treatment and/or participate in clinical trials. At the individual patient level, competing risk, perceived efficacy of treatment, and various levels of patient/physician preferences all contribute to heterogeneity in treatment decision-making. At the population level, the economic impact of this variability is significant. Costs incurred in the prevention, diagnosis, treatment and surveillance of cancer are rising at a rate disproportionate to what healthcare systems are able to afford. Cost-effectiveness research can be employed to determine the suitability of radiotherapy in elderly cancer populations through modeling or in the context of clinical trials. Using stereotactic radiotherapy in early stage lung cancer as an example, the principals of cost-effectiveness research will be explored. Concepts such as cost calculations, quality adjusted life expectancy, utilities, and incremental cost effectiveness ratios will be introduced.
SP-0244 From co-morbidity and toxicity to quality of life: A black hole in economic evaluations of radiotherapy? E. Moser 1 1 Fundação Champalimaud, Department of Radiotherapy, Lisboa, Portugal
Cancer is increasingly becoming a disease affecting the lives of the elderly, especially in more developed countries. Over the last 30 years, many patients have experienced the mortality lowering benefits of earlier diagnosis and more effective treatments. At the same time, the elderly population is demographically fast increasing, pronouncing even higher prevalence and incidence rates in the near future. Among other co-morbidities, second or third cancers are not an exception any more. Because of large individual variations in physical and mental conditions and personal preference of the patient and/or family, the treatment decisions seem difficult to fit into guidelines. Inclusion in clinical trials is rare. Overall, elderly receive (adjuvant) radiotherapy and chemotherapy less often, probably because of fear for higher rate of complications. In clinical surveys, however, elderly don´t suffer from more complications than younger patients, except for cardiac complications and postoperative death. For most tumours relative survival is lower for the elderly, except for patients with colon cancer, prostate cancer or indolent NHL. Co-morbidity seems to have an independent prognostic effect, except for tumours with a very poor prognosis. Alternative research strategies need to be sought to improve insights on causes of death in this population. Special attention is needed for the economical impact of over-versus under treatment. Both palliative care and complications generate high costs, but reports on costs are rare. Often quality of life surveys are lacking late outcome and decisionmaking trade offs. Registry based surveys can help insights in population-based decision-making, but are lacking comorbidity and toxicity data. Guidelines are needed to reduce over-treatment but also under-treatment, taking into account life-expectancy and comorbidities in all our cancer patients.
SP-0245
Is it time to design specific radiotherapy trials for the elderly, and how can we integrate the economic perspective? J. Van Loon 1 1 MAASTRO Clinic, Radiation Oncology, Maastricht, The Netherlands More than 60% of cancer patients is older than 65 years, a figure that only will increase the coming decades. As elderly patients are underrepresented in clinical trials, treatment recommendations for the general population cannot straightforwardly be extrapolated to the elderly. It is anticipated that intensified treatment regimens are less effective in elderly due to physiologic changes occurring with aging. Furthermore, higher toxicity rates are expected given the high rates of comorbidities and generally poorer performance status. Hence, the balance between the benefits and risks of a treatment will be different for this patient group. In fact, this balance will be different for each individual elderly patient: although it is reasonable to spare the patient with severe comorbidities or a bad performance status an intensive treatment from which he is unlikely to benefit and that might even decrease quality of life (QoL), the one that is medically fit may benefit from such an intensive treatment. Furthermore, given the limited life expectancy, QoL and preservation of independence and cognition are important to take into account. For these reasons, there is an urgent need to design clinical trials specific for the elderly, build evidence to guide treatment selection in this group and implement it in clinical practice. First, reliable tools are needed to distinguish the subgroup of fit patients from frail patients, i.e. those expected to experience important toxicity. Until now, this decision is rather subjective as it is based primarily on the physician's perception whether a patient is deemed fit enough to undergo a certain treatment. Geriatric assessments have shown to be more predictive for survival, dependency and toxicities than age or performance status in elderly treated with chemotherapy (Freyer, Ann Oncol 2005; Hurria, JCO 2011; Maione JCO 2005), but these have not been validated for radiotherapy. The fact that a full geriatric assessment is time consuming and is not always reimbursed makes it difficult to implement in routine clinical practice. Therefore, the EORTC recommends a minimum dataset data (MinDS) to be collected, which takes max 5 minutes to complete (Pallis, Ann Oncol 2011). It is anticipated that this
